On Jun. 22, 2020, Catalent announced that it had signed an agreement with ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies, to work on the development of a potential treatment for adults with advanced Coronavirus Disease 2019. Under the terms of the agreement, Catalent will be developing two oral dosage forms of ViralClear’s broad-spectrum anti-viral agent, merimepodib: a solution and a solid oral dosage form.